See associations below
|I ANXA1||Annexin A1, hairy cell, B-cell lymphoma|
|I BCL 2||BCL2 follicular lymphoma, apoptosis|
|I BCL 6||BCL6 follicle center B-cells|
|I CD20||CD20 pan B-cell|
|I CD23||CD23 activated B-cell 125|
|I CD79a||CD79a B-cell, plasma cells|
|I CD10||CD10, Common ALL antigen|
|I CYCLIN||Cyclin D1/PRAD1, mantle cell lymphoma|
|I MUM1||MUM1, multiple myeloma oncogene|
|I PAX 5||PAX-5, B-cell transcription factor|
|* Performed at affiliate laboratory|
Technical component (TC) available for all markers
Ship ambient. In extreme hot weather, ship with a cool pack.
Inadequate fixation; Improper labeling
Marker and tissue specific
Results are reviewed by a board-certified pathologist to determine if tissues are positive or negative for the marker. These results may be used to assist in determining appropriate patient therapy or treatment.
Immunohistochemistry (IHC) combines the principles of histochemistry with the high degree of molecular specificity of the antibody-antigen reaction. The use of an enhanced-polymer detection system provides many benefits including increased sensitivity, fewer procedural steps as compared to conventional techniques, and a reduction in non-specific background staining. MPLN offers a range of markers by IHC including hematologic, tissue specific, infectious agents and proliferation antigens.